Xeris Biopharma - XERS Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XERS shares.
View XERS analyst ratings or view top-rated stocks.

5 brokerages have issued 12-month price objectives for Xeris Biopharma's shares. Their XERS share price forecasts range from $4.00 to $6.50. On average, they anticipate the company's stock price to reach $5.70 in the next year. This suggests a possible upside of 298.6% from the stock's current price.
View analysts price targets for XERS or view top-rated stocks among Wall Street analysts.

Xeris Biopharma's stock was trading at $2.93 at the start of the year. Since then, XERS stock has decreased by 51.2% and is now trading at $1.43.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our XERS earnings forecast.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) posted its earnings results on Tuesday, November, 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.02. The business earned $11.04 million during the quarter, compared to the consensus estimate of $10.43 million. Xeris Biopharma had a negative net margin of 134.49% and a negative trailing twelve-month return on equity of 161.24%. During the same period in the prior year, the company posted ($0.35) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and OrganiGram (OGI).

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS."

Xeris Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (9.54%), BlackRock Inc. (6.07%), Vanguard Group Inc. (4.80%), Armistice Capital LLC (1.85%), State Street Corp (1.60%) and Renaissance Technologies LLC (0.41%). Insiders that own company stock include John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends.

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XERS stock can currently be purchased for approximately $1.43.

Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $193.81 million and generates $49.59 million in revenue each year. The company earns $-122,720,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

The company employs 294 workers across the globe.

Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for the company is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com.